A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Daxdilimab (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Amgen; Horizon Therapeutics plc
- 09 Nov 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 08 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 02 May 2023 According to a Horizon Therapeutics plc media release, the first patient has been enrolled in the study.